Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension

Cardiovascular Drugs and Therapy

Volumn 12, Issue 5, 1998, Pages 469-474

  Mitsunami, Kenichi ^a   Inoue, Shinji ^a   Maeda, Keiko ^a   Endoh, Shigeru ^a   Takahashi, Masayuki ^a   Okada, Mamoru ^a   Sugihara, Hideki ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Angiotensin II AT1 receptor antagonist; Candesartan cilexetil; Cardiac hypertrophy; Echocardiography; Essential hypertension; Magnetic resonance imaging

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0032442218     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007754100351     Document Type: Article

References (23)

1. Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975;51:606-613.
2. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317:787-792.
3. Dunn FG, Plingle SD. Left ventricular hypertrophy and myocardial ischemia in systemic hypertension. Am J Cardiol 1987;60:191-221.
4. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.
5. Kannel WB, Castelli WP, McNamara PM, et al. Role of blood pressure in the development of congestive heart failure. N Engl J Med 1972;287:781-787.
6. Dahlöf B: The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. J Hypertens 1993;11(Suppl. 3):S29-S35.
7. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991; 83:13-25.
8. Himmelmann A, Svensson A, Bergbrant A, Hansson L. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens 1996;10:729-734.
9. Cheung B. Increased left-ventricular mass after losartan treatment. Lancet 1997;349:1743-1744.
10. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1- [[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1- [[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H -benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-120.
11. Yamaoka O, Yabe T, Okada M, et al. Evaluation of left ventricular mass: Comparison of ultrafast computed tomography, magnetic resonance imaging, and contrast left ventriculography. Am Heart J 1993;126:1372-1379.
12. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
13. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976;37:7-11.
14. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57: 450-458.
15. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation 1987;75 (Suppl. I):I26-I33.
16. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
17. Ogihara T, Higashimori K, Masuo K, Mikami H. Pilot study of a new angiotensin II receptor antagonist, TCV-116: Effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 1993;15:684-691.
18. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
19. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation 1997;95:2007-2014.
20. Neaton JD, Grimm RH Jr., Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270:713-724.
21. Savage DD, Drayer JIM, Henry WL, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979;59:623-632.
22. Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MR imaging. Radiology 1988; 169:495-498.
23. Germain P, Roul G, Kastler B, et al. Inter-study variability in left ventricular mass measurement. Comparison between M-mode echography and MRI. Eur Heart J 1992;13: 1011-1019.